Matthew Common

Matthew Common

Auto-generated profile, based on publicly available information

Matthew Common

Department of Radiology, Beaumont Hospital, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Clinical Radiology
Verified
Journal Article
Closed access
PRP. Rohan
P. Rohan
MCM. Common
M. Common
JRJ. Ryan
J. Ryan
DMD. Mulholland
D. Mulholland
AOA. O'Shea
A. O'Shea

27 January 2026 in Clinical Radiology
Verified
Journal Article
Closed access
RLR.J. Lee
R.J. Lee
ETE. Tong
E. Tong
JAJ. Alderson
J. Alderson
MCM. Common
M. Common
ACA. Clark
A. Clark
MLM.J. Lee
M.J. Lee

22 January 2026 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
RBRichard Bruen
Richard Bruen
SSSophie Sabherwal
Sophie Sabherwal
HBHayley Briody
Hayley Briody
MCMatthew Common
Matthew Common
SSSneha Singh
Sneha Singh
SLSeamus Looby
Seamus Looby
A resurgence in recreational misuse of nitrous oxide has been observed in the post-coronavirus disease 2019 (COVID) pandemic era and consequently there has been a surge in cases of nitrous oxide-induced subacute combined degeneration of the cord (N2O-SACD). It is essential that physicians have an awareness of clinical history, neurologic findings, laboratory investigations, and characteristic features on MR imaging that may suggest a diagnosis of N2O-SACD. This retrospective, hospital-based case series was conducted in a tertiary medical referral center and 1 of 2 National Neuroscience Centers in Ireland. Retrieval of cases was achieved by a keyword search of a radiology PACS archive, using the terms such as "subacute combined degeneration of the cord" and "SACD" to search clinical indications for MR imaging and radiology reports at the institution from July 1, 2012 to December 31, 2024. Thirty-three patients underwent MRI investigations for suspected subacute combined degeneration of the cord. Twenty-five reported nitrous oxide use. Fourteen of those with reported nitrous oxide use and clinical symptoms had MRI findings suggestive of subacute combined degeneration of the cord. Most prominent symptoms were distal paresthesia (100%), weakness (52%), and ataxia (36%). All cases of N2O-SACD occurred between 2020 and 2024. The cervical cord was affected in all 14 MRI-positive patients with a characteristic inverted V sign synonymous with subacute combined degeneration of the cord identified in all 14 (100%). This case series reflects the growing incidence and prevalence of N2O-SACD. Presentations occurring exclusively between 2020-2024 correlate with the COVID-19 pandemic and its aftermath, which aligns with reported increased misuse across Europe at this time. MRI cervicothoracic spine with T1, T2, and STIR sagittal and T2 axial sequences should suffice for radiologic diagnosis and should be interpreted in conjunction with clinical, laboratory, and, in some cases, electrophysiologic findings.

1 November 2026 in Stroke
Verified
Journal Article
Closed access
GSGhil Schwarz
Ghil Schwarz
ARAngelo Cascio Rizzo
Angelo Cascio Rizzo
GAGareth Ambler
Gareth Ambler
PWPawel Wrona
Pawel Wrona
ASAgnieszka Slowik
Agnieszka Slowik
MSMaria Sessa
Maria Sessa
BACKGROUND: Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. METHODS: We performed a secondary analysis of the CAN-REST registry (Contrast-Associated Nephropathy After Endovascular Stroke Treatment), a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. RESULTS: Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07–2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours—well below Kidney Disease: Improving Global Outcomes threshold—was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01–1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13–1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93–0.99]; adjusted odds ratio, 0.74 [95% CI, 0.65–0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. CONCLUSIONS: Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06596603.